University of Luebeck Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2017
NCT03146247
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Prof. Dr. med. Ingo Eitel

Active Ingredients

Drugs in Phase 4 Trials (1)

apremilast (otezla) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psoriasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1